Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar i disorder

Neuropsychopharmacology

Volumn 38, Issue 3, 2013, Pages 468-475

  Soeiro De Souza, Márcio Gerhardt ^a   Salvadore, Giacomo ^b   Moreno, Ricardo Alberto ^a   Otaduy, Maria Concepción Garcia ^a   Chaim, Kalil T ^a   Gattaz, Wagner F ^a   Zarate Jr , Carlos A ^b   MacHado Vieira, Rodrigo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Bcl 2; bipolar disorder; calcium; depression; glutamate; spectroscopy

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CREATINE; GLUTAMIC ACID; LITHIUM; NEUROLEPTIC AGENT; PROTEIN BCL 2;

ADULT; ANTERIOR CINGULATE; ARTICLE; BIPOLAR I DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANALYSIS; FUNCTIONAL NEUROIMAGING; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEMI STRUCTURED INTERVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; BIPOLAR DISORDER; FEMALE; GLUTAMIC ACID; GYRUS CINGULI; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-BCL-2; UP-REGULATION; YOUNG ADULT;

EID: 84872489243     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.203     Document Type: Article

References (62)

1. Ahmad S, Fowler LJ, Whitton PS (2005). Effects of combined lamotrigine and valproate on basal and stimulated extracellular amino acids and monoamines in the hippocampus of freely moving rats. Naunyn-Schmiedeberg's Arch Pharmacol 371: 1-8.
2. Altamura CA, Mauri MC, Ferrara A, Moro AR, D'Andrea G, Zamberlan F (1993). Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 150: 1731-1733.
3. Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH (2007). Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 32: 1888-1902.
4. Beneyto M, Meador-Woodruff JH (2008). Lamina-specific abnorm-alities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 33: 2175-2186.
5. Bhagwagar Z, Wylezinska M, Jezzard P, Evans J, Ashworth F, Sule A et al (2007). Reduction in occipital cortex gamma-aminobu-tyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. Biol Psychiatry 61: 806-812.
6. Chao DT, Korsmeyer SJ (1998). BCL-2 family: regulators of cell death. Annu Rev Immunol 16: 395-419.
7. Chen R, Valencia I, Zhong F, McColl KS, Roderick HL, Bootman MD et al (2004). Bcl-2 functionally interacts with inositol 1,4,5-trisphosphate receptors to regulate calcium release from the ER in response to inositol 1,4,5-trisphosphate. J Cell Biol 166: 193-203.
8. Colla M, Schubert F, Bubner M, Heidenreich JO, Bajbouj M, Seifert F et al (2009). Glutamate as a spectroscopic marker of hippo-campal structural plasticity is elevated in long-term euthymic bipolar patients on chronic lithium therapy and correlates inversely with diurnal cortisol. Mol Psychiatry 14: 696-704, 647.
9. Drevets WC (2000). Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog Brain Res 126: 413-431.
10. Drevets WC, Ongür D, Price JL (1998). Neuroimaging abnormalities in the subgenual prefrontal cortex: implications for the pathophysiol-ogy of familial mood disorders. Mol Psychiatry 3, 220-226, 190-191.
11. Drevets WC, Savitz J, Trimble M (2008). The subgenual anterior cingulate cortex in mood disorders. CNS Spectrums 13: 663-681.
12. DSM-IV, PATFO (2000). Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. American Psychiatric Publishing.
13. Du J, Suzuki K, Wei Y, Wang Y, Blumenthal R, Chen Z et al (2007). The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsy-chopharmacology 32: 793-802.
14. Eastwood SL, Harrison PJ (2010). Markers of glutamate synaptic transmission and plasticity are increased in the anterior cingulate cortex in bipolar disorder. Biol Psychiatry 67: 1010-1016.
15. First MB, Spitzer RL, Williams JB (1996). Structured Clinical Interview for DSM-IV Axis I Disorders SCID-I. American Psychiatric Press: Washington, DC
16. Foland-Ross LC, Thompson PM, Sugar CA, Madsen SK, Shen JK, Penfold C et al (2011). Investigation of cortical thickness abnormalities in lithium-free adults with bipolar I disorder using cortical pattern matching. Am J Psychiatry 168: 530-539.
17. Francis PT, Poynton A, Lowe SL, Najlerahim A, Bridges PK, Bartlett JR et al (1989). Brain amino acid concentrations and Ca2 + -dependent release in intractable depression assessed antemortem. Brain Res 494: 315-324.
18. Friedman SD, Dager SR, Parow A, Hirashima F, Demopulos C, Stoll AL et al (2004). Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. Biol Psychiatry 56: 340-348.
19. Frye MA, Watzl J, Banakar S, O'Neill J, Mintz J, Davanzo P et al (2007). Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression. Neuropsychophar-macology 32: 2490-2499.
20. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurgery Psychiatry 23: 56-62.
21. Hammonds MD, Shim SS (2009). Effects of 4-week treatment with lithium and olanzapine on levels of brain-derived neurotrophic factor, B-cell CLL/lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element-binding protein in the sub-regions of the hippocampus. Basic Clin Pharmacol Toxicol 105: 113-119.
22. Hashimoto K, Sawa A, Iyo M (2007). Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 62: 1310-1316.
23. Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang DM (2002). Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphoryla-tion. J Neurochemistry 80: 589-597.
24. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ (1993). Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75: 241-251.
25. Hokin LE, Dixon JF, Los GV (1996). A novel action of lithium: stimulation of glutamate release and inositol 1,4,5 trisphosphate accumulation via activation of the N-methyl D-aspartate receptor in monkey and mouse cerebral cortex slices. Adv Enzyme Regul 36: 229-244.
26. Kim H-W, Rapoport SI, Rao JS (2010). Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiol Disease 37: 596-603.
27. Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH (1982). Increased serum glutamate in depressed patients. Archiv für Psychiatrie und Nervenkrankheiten 232: 299-304.
28. Kumar A, Singh RL, Babu GN (2010). Cell death mechanisms in the early stages of acute glutamate neurotoxicity. Neurosci Res 66: 271-278.
29. Laitinen J, Samarut J, Hölttä E (1994). A nontoxic and versatile protein salting-out method for isolation of DNA. Biotechniques 17: 316-322.
30. Lan MJ, McLoughlin GA, Griffin JL, Tsang TM, Huang JT, Yuan P (2009). Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder. Mol Psychiatry 14: 269-279.
31. Lazarewicz JW, Salińska E (1993). Role of calcium in glutamate-mediated toxicity: mechanisms of calcium fluxes in rabbit hippocampus in vivo investigated with microdialysis. Acta Neurobiologiae Experimentalis 53: 3-13.
32. Levine J, Panchalingam K, Rapoport A, Gershon S, McClure RJ, Pettegrew JW (2000). Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry 47: 586-593.
33. Lien R, Flaisher-Grinberg S, Cleary C, Hejny M, Einat H (2008). Behavioral effects of Bcl-2 deficiency: implications for affective disorders. Pharmacol Rep 60: 490-498.
34. Liu J, Blond BN, van Dyck LI, Spencer L, Wang F, Blumberg HP et al (2012). Trait and state corticostriatal dysfunction in bipolar disorder during emotional face processing. Bipolar Disorders 14: 432-441.
35. Machado-Vieira R, Manji HK, Zarate CA (2009b). The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 15: 525-539.
36. Machado-Vieira R, Pivovarova NB, Stanika RI, Yuan P, Wang Y, Zhou R et al (2011). The Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endo-plasmic reticulum calcium release in subjects with bipolar disorder. Biol Psychiatry 69: 344-352.
37. Machado-Vieira R, Salvadore G, Ibrahim LA, Diaz-Granados N et al (2009a). Targeting glutamatergic signaling for the develop-ment ofnovel therapeutics for mood disorders. Curr Pharmaceut Design 15: 1595-1611.
38. Manji H (2008). Bcl-2: A key regulator of affective resilience in the pathophysiology and treatment of severe mood disorders. Biol Psychiatry 63(Suppl 1): 243S.
39. Manji HK, Moore GJ, Chen G (2000). Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J Clin Psychiatry 61(Suppl 9): 82-96.
40. Mauri MC, Ferrara A, Boscati L, Bravin S, Zamberlan F, Alecci M et al (1998). Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 37: 124-129.
41. Mitani H, Shirayama Y, Yamada T, Maeda K, Ashby CR Jr, Kawahara R et al (2006). Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuro-Psychopharmacol Biol Psychiatry 30: 1155-1158.
42. National Center for Biotechnology Information (2012). dbSNP. 2012th edn, Available at: http://www.ncbi.nlm.nih.gov/projects/ SNP/snp-ref.cgi?rs= 956572(accessed 18 July 2012).
43. Nierenberg AA, DeCecco LM (2001). Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 62(Suppl 16): 5-9.
44. Ongur D, Ferry AT, Price JL (2003). Architectonic subdivision of the human orbital and medial prefrontal cortex. J Comparative Neurol 460: 425-449.
45. Ongur D, Jensen JE, Prescot AP, Stork C, Lundy M, Cohen BM et al (2008). Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry 64: 718-726.
46. Ongür D, Drevets WC, Price JL (1998). Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 95: 13290-13295.
47. Phillips ML, Drevets WC, Rauch SL, Lane R (2003). Neurobiology of emotion perception I: The neural basis of normal emotion perception. Biol Psychiatry 54: 504-514.
48. Provencher SWS (1993). Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magnet Resonance Med 30: 672-679.
49. Provencher (2012). LCModel and LCM gui User's Manual. Avai-lable at http://s-provencher.com/pages/lcm-manual.shtml.
50. Salvadore G, Nugent AC, Chen G, Akula N, Yuan P, Cannon DM et al (2009). Bcl-2 polymorphism influences gray matter volume in the ventral striatum in healthy humans. Biol Psychiatry 66: 804-807.
51. Scarr E, Pavey G, Sundram S, MacKinnon A, Dean B (2003). Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder. Bipolar Disorders 5: 257-264.
52. Senaratne R, Milne AM, MacQueen GM, Hall GB (2009). Increased choline-containing compounds in the orbitofrontal cortex and hippocampus in euthymic patients with bipolar disorder: a proton magnetic resonance spectroscopy study. Psychiatry Res 172: 205-209.
53. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59, (Suppl 20) 22-33; quiz 34-57.
54. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG et al (2000). Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch General Psychiatry 57: 841-849.
55. Uemura T, Green M, Corson TW, Perova T, Li PP, Warsh JJ (2011). Bcl-2 SNP rs956572 associates with disrupted intracellular calcium homeostasis in bipolar I disorder. Bipolar Disorders 13: 41-51.
56. Wang J-F, Shao L, Sun X, Young LT (2009). Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disorders 11: 523-529.
57. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C et al (2009). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disorders 11: 225-255.
58. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978). A rating scale for mania: reliability, validity and sensitivity. British J Psychiatry 133: 429-435.
59. Yüksel C, Ongur D (2010). Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry 68: 785-794.
60. Zarate C Jr, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, Salvadore G (2010). Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry 18: 293-303.
61. Zhong LT, Kane DJ, Bredesen DE (1993). BCL-2 blocks glutamate toxicity in neural cell lines. Brain research. Molecular Brain Res 19: 353-355.
62. Zimmermann AK, Loucks FA, Schroeder EK, Bouchard RJ, Tyler KL et al (2007). Glutathione binding to the Bcl-2 homology-3 domain groove: a molecular basis for Bcl-2 antioxidant function at mitochondria. J Biol Chemistry 282: 29296-29304.